Tuesday broker round-up
17th Mar 2020 13:00
(Sharecast News) - Ti Fluid Systems: Citigroup downgrades to neutral with a target price of 140p.
Read moreAstraZeneca posts mixed update on lung cancer drug R&D
17th Mar 2020 09:02
(Sharecast News) - Pharmaceuticals giant AstraZeneca issued a mixed update on recent research and development work on Tuesday.
Read moreTrump set to declare national emergency in US, freeing up funding
13th Mar 2020 16:53
(Sharecast News) - The US is expected to declare a national emergency at the end of the week and call for a coordinated international response to contain the coronavirus and its economic fallout.
Read moreAstraZeneca reports disappointing results from latest 'Lynparza' trial
12th Mar 2020 07:32
(Sharecast News) - AstraZeneca, alongside its partner MSD, announced high-level results from the phase 3 'GY004' trial on Thursday, which examined the efficacy and safety of the potential new medicine 'cediranib' added to 'Lynparza', or olaparib, when compared to platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
Read moreAstraZeneca bladder treatment fails to met trial endpoint
6th Mar 2020 07:19
(Sharecast News) - AstraZeneca said its Imfinzi bladder cancer treatment did not meet primary endpoints in the phase three DANUBE trial against standard-of-care (SoC) chemotherapy for patients with an advanced stage of the disease.
Read moreTuesday broker round-up
25th Feb 2020 13:15
(Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.
Read moreAstraZeneca offloads 'Movantik' rights to RedHill Biopharma
25th Feb 2020 07:30
(Sharecast News) - AstraZeneca has agreed to sublicense its global rights to 'Movantik', or naloxegol, excluding Europe, Canada and Israel, to RedHill Biopharma, it announced on Tuesday.
Read moreThursday broker round-up
20th Feb 2020 13:40
(Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.
Read moreDirector dealings: AstraZeneca director makes share purchase
19th Feb 2020 16:50
(Sharecast News) - AstraZeneca revealed on Wednesday that non-executive director Michel Demare had acquired 700 ordinary shares in the FTSE 100-listed pharmaceutical giant.
Read moreMonday broker round-up
17th Feb 2020 13:05
(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
Read moreLondon midday: Stocks steady as some analysts sound hopeful note on coronavirus
14th Feb 2020 11:27
(Sharecast News) - Stocks have recovered from an early dip after the World Health Organisation said overnight that the spike in coronavirus cases in China on Thursday are not new infections.
Read moreLondon open: Stocks little changed as traders reassess coronavirus risks
14th Feb 2020 08:00
(Sharecast News) - Stocks slipped in early trading as traders grappled with the difficulty of pinpointing how far along China really was in controlling the outbreak of a new coronavirus in the country.
Read moreAstraZeneca profit falls as costs and writedowns increase
14th Feb 2020 07:03
(Sharecast News) - AstraZeneca's annual profit fell 14% as rising costs and higher asset writedowns offset sales increases at the pharmaceutical company.
Read moreAstra reports positive results from stroke, gastric cancer trials
27th Jan 2020 09:24
(Sharecast News) - AstraZeneca said high-level results from from a phase three trial of its Brilinta drug used in conjunction with aspirin produced a "statistically significant and clinically meaningful" fall in the risk of the primary composite endpoint of stroke and death, compared with aspirin alone.
Read moreAstraZeneca sells hypertension drug rights; Ends Allergan deal
27th Jan 2020 07:53
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
Read more